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Meconium aspiration syndrome (MAS) is a complex respiratory disease of the term and near-term neonate. Inhalation of
meconium causes airway obstruction, atelectasis, epithelial injury, surfactant inhibition, and pulmonary hypertension, the chief
clinical manifestations of which are hypoxaemia and poor lung compliance. Supplemental oxygen is the mainstay of therapy for
MAS, with around one-third of infants requiring intubation and mechanical ventilation. For those ventilated, high ventilator
pressures, as well as a relatively long inspiratory time and slow ventilator rate, may be necessary to achieve adequate oxygenation.
High-frequency ventilation may oﬀer a beneﬁt in infants with refractory hypoxaemia and/or gas trapping. Inhaled nitric oxide
is eﬀective in those with pulmonary hypertension, and other adjunctive therapies, including surfactant administration and lung
lavage,shouldbeconsideredinselectedcases.Withjudicioususeofavailablemodesofventilationandadjunctivetherapies,infants
with even the most severe MAS can usually be supported through the disease, with an acceptably low risk of short- and long-term
morbidities.
1.Introduction
Meconium aspiration syndrome (MAS) is complex respira-
tory disease of the term and near-term neonate that contin-
ues to place a considerable burden on neonatal intensive care
resources worldwide. The condition has features that make
it stand alone amongst neonatal respiratory diseases—the
unique combination of airﬂow obstruction, atelectasis, and
lung inﬂammation, the high risk of coexistent pulmonary
hypertension, and the fact of these occurring in a term infant
with a relatively mature lung structurally and biochemically.
For all these reasons, management of MAS, and in particular
the ventilatory management of MAS, has been a diﬃcult
challenge for neonatologists down the years. This paper
focuses on application of mechanical respiratory support in
MAS, as well as the role of adjunctive respiratory therapies.
For the purpose of the paper, MAS is deﬁned as respiratory
distress occurring soon after delivery in a meconium-stained
infant, which is not otherwise explicable and is associated
with a typical radiographic appearance [1].
2.Pathophysiology andEffects on Gas
Exchange andLungCompliance
Lung dysfunction in MAS is a variable interplay of several
pathophysiological disturbances, chief amongst which are
airway obstruction, atelectasis, and pulmonary hyperten-
sion. Meconium, the viscid pigmented secretion of the fetal
intestinal tract [2], is a noxious substance when inhaled,
producing one of the worst forms of aspiration pneumonitis
encountered in humans. Meconium has many adverse
biophysical properties, including high tenacity (stickiness)
[3], very high surface tension (215mN/m) [3], and potent
inhibitionofsurfactantfunction[4–6].Itisalsodirectlytoxic
to the pulmonary epithelium [7], causing a haemorrhagic
alveolitis with high concentrations of protein and albumin
in the alveolar space [8]. Meconium contains substances that
are chemotactic to neutrophils [9] and activate complement
[10] and may in addition be vasoactive [11]. These adverse
properties of meconium are reﬂected in the pathophysiolog-
ical disturbances known to occur in MAS [12].2 International Journal of Pediatrics
Once inhaled, migration of meconium down the tra-
cheobronchial tree initially causes obstruction of airways of
progressively smaller diameter [13–15]. At least in exper-
imental MAS, there can be a considerable component of
“ball-valve” obstruction, with high resistance to airﬂow in
expiration, resulting in gas trapping distal to the obstruction
[14].Ifglobalindistribution, highfunctionalresidualcapac-
ity (FRC) may result, although only in a small proportion
of infants with MAS is there measurably high FRC [16, 17],
and even then only transiently [17]. For most infants with
MAS, the predominant consequence of airway obstruction
with meconium is downstream atelectasis [18]. The patchy
nature of the airway obstruction results in a juxtaposition
of atelectatic and normally aerated lung units, which has
been clearly shown histologically [18] ,a n di sr e ﬂ e c t e di nt h e
patchy opaciﬁcation typically noted on chest X-ray in MAS
(Figure 1)[ 19].
After migration to the level of the alveoli, meconium
induces a combination of haemorrhagic alveolitis and sur-
factant inhibition. Meconium is toxic to the alveolar epithe-
lium [7, 20], causing disruption of the alveolocapillary
barrier and an exudative oedema not unlike that seen in
acute respiratory distress syndrome. The underlying lung
interstitium shows inﬂammatory cell inﬁltrate [13, 15], and
there is a cytokine release in part related to complement
activation [10, 21, 22]. Moreover, meconium causes a potent
dose-dependent inhibition of surfactant function [4–6] and,
along with ﬁbrinogen and haemoglobin in the exudate [23,
24], impairs the capacity of endogenous surfactant to reduce
surface tension. Stability of alveoli at end-expiration is thus
compromised [25], as is the capacity to clear oedema ﬂuid
fromthe airspaces[26].Theresultantmicroatelectasiscauses
variable degrees of ventilation-perfusion mismatch or, worse
still, intrapulmonary shunt.
The most prominent and consistent physiological eﬀects
resulting from meconium injury are hypoxaemia and
decreased lung compliance. Some degree of hypoxaemia is
universal in symptomatic MAS, contributed to by many
of the above-mentioned noxious eﬀects of meconium.
DisturbancesofoxygenationinMASmayrelatetoatelectasis,
overdistension, pulmonary hypertension, or a combination
of these. A challenging aspect of the management of MAS is
to discern which mechanism of hypoxaemia is the predom-
inant one in any given infant at any given time. Particularly
where there is prominent airway obstruction or pronounced
atelectasis, hypoxaemia may be accompanied by respiratory
acidosis with CO2 retention related to hypoventilation.
Lung or respiratory system compliance is usually sig-
niﬁcantly impaired in infants requiring ventilation with
MAS [17, 22, 27–30]. Experimental studies have indicated
that decreased compliance may be related to hyperinﬂation
secondary to “ball-valve” airway obstruction [14], and
the combination of poor compliance and high FRC has
been demonstrated in some cases of MAS [17]. For most
infants with MAS, in whom FRC is normal or low [17],
poor compliance relates to global or regional atelectasis.
Application of mechanical ventilation further complicates
the picture, potentially leading to overdistension of relatively
unaﬀected lung regions which, due to their relatively long
time constant, may empty incompletely during the ventilator
expiratory cycle, especially at fast ventilator rates [31]. Respi-
ratory resistance has also been noted to be increased in some
studies, but variations in the technique of measurement
make interpretation of these results diﬃcult.
MAS is frequently accompanied by persistent pulmonary
hypertension of the newborn (PPHN) [32], with many fac-
tors contributing to its development, including low pO2 and
pH, coexistent intrauterine asphyxia, and possibly vasoactive
substances in the meconium itself [33].
3. StepwiseApproachto Respiratory Support
3.1.OxygenTherapy. Supplementaloxygenadministrationis
the mainstay of treatment for MAS and in many less severe
cases is the only therapy required [34]. Some ventilated
infantswithMASreceivehighinspiredoxygenconcentration
for long periods, with few apparent adverse eﬀects. Ther-
apeutic considerations in cases of persistently high oxygen
requirement are outlined in Table 1.
As with the preterm infant, moment-by-moment adjust-
ment of oxygen concentration (or ﬂow) in infants with MAS
is guided oxygen saturation measured by pulse oximetry
(SpO2). Given the high incidence of right-to-left ductal
shunting related to pulmonary hypertension, a pre-ductal
SpO2 is preferable, with the target range for SpO2 being
higher than that for the preterm infant, usually between 94
and 98%. In ventilated infants, oxygen therapy can also be
monitored by blood gas sampling from an intra-arterial line,
preferably in a preductal position in the right radial artery.
Suggested target pO2 range is 60–100mm Hg (preductal).
Where there is considerable PPHN, titration of FiO2 using
postductal pO2 values is not advisable.
3.2. Continuous Positive Airway Pressure. Of all infants re-
quiring mechanical respiratory support because of MAS,
approximately 10–20% are treated with continuous positive
airway pressure (CPAP) alone [34–36]. Additionally, up
to one-quarter of infants requiring intubation with MAS
receive CPAP before and/or after their period of ventilation
[36]. CPAP for such infants can be eﬀectively delivered by
binasal prongs or a single nasal prong, typically with a CPAP
pressure of 5–8cm H2O. Tolerance of the CPAP device may
be limited given the relative maturity of infants with MAS,
and on occasions the associated discomfort will exacerbate
pulmonary hypertension to the point where intubation
becomes necessary.
3.3.Intubation. Approximatelyone-thirdofallinfantswitha
diagnosis of MAS require intubation and mechanical ven-
tilation [33, 37]. Indications for intubation of infants with
MAS include (a) high oxygen requirement (FiO2 > 0.8),
(b) respiratory acidosis, with arterial pH persistently less
than 7.25, (c) pulmonary hypertension, and (d) circulatory
compromise, with poor systemic blood pressure and perfu-
sion [38]. Except in emergency circumstances, intubation of
infants with MAS should be performed with premedication.
Signiﬁcant endotracheal tube leak is a major barrier toInternational Journal of Pediatrics 3
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Figure 1:ChestX-rayappearancesinventilatedinfantswithMAS.(a)TypicalappearanceofMASshowing“ﬂuﬀy”opaciﬁcationwidespread
throughoutthelungﬁelds.(b)Markedatelectasisinaninfantwithprofoundhypoxaemia.(c)Hyperinﬂationandgastrapping,withanarrow
cardiac waist, ﬂattened diaphragms, and intercostal bulging of the lung.
Table 1: Approach to hypoxaemia in MAS.
I ft h e r ei sm a r k e dg l o b a lo rr e g i o n a la t e l e c t a s i s ,c o n s i d e r :
(i) Increasing PEEP to improve end-expiratory lung volume
(ii) Increasing PIP to recruit atelectatic lung units
(iii) Increasing inspiratory time to facilitate the recruiting eﬀect of
PIP
(iv) Use of HFOV with suﬃcient distending pressure to recruit
atelectatic lung units
(v) Use of HFJV with suﬃcient PEEP to maintain FRC and
conventional breath PIP to recruit atelectatic lung units
(vi) Exogenous surfactant
(vii) Lung lavage
If there is obvious gas trapping, consider:
(i) Decreasing PEEP (but may lose recruitment of areas prone to
atelectasis)
(ii) Decreasing inspiratory time and increasing expiratory time
(iii) Use of HFJV with low PEEP, low frequency (240–360bpm),
and minimal CMV breaths
(iv) Use of HFOV with relatively low PAW and low frequency (5-
6Hz)
If there is pulmonary hypertension, consider:
(i) Correction of potentiating factors—hypoglycaemia, hypocal-
caemia, hypomagnesaemia, polycythaemia, hypothermia, pain
(ii) Bolstering systemic blood pressure to reduce right to left ductal
shunt—volume expansion, pressor agents
(iii) Improving right ventricular function—inotrope infusion
(iv) Selective pulmonary vasodilators—inhaled nitric oxide
eﬀective ventilation in infants with MAS, and in most cases
a size 3.5mm internal diameter endotracheal tube will be
required. Once intubated, tolerance of the endotracheal
tube will almost certainly require ongoing sedation with
infusions of an opiate (e.g., morphine or fentanyl) [39],
possibly supplemented with a benzodiazepine. Additionally,
continuation of muscle relaxant drugs is oftenhelpful during
the stabilisation period after intubation, particularly in
infants with coexistent pulmonary hypertension.
3.4. Conventional Mechanical Ventilation. Despite more than
four decades of mechanical ventilation for infants with MAS,
the ventilatory management of the condition remains largely
in the realm of “art” rather than “science”, with very few
clinical trials upon which to base deﬁnitive recommenda-
tions. Physiological principles and published experience do,
however, allow some guiding principles to be put forward for
conventional ventilation strategy in MAS.
3.4.1. Choosing a Mode of Ventilation. Ventilation mode and
the value of patient-triggering have been incompletely stud-
ied in MAS. Two randomised trials of patient-triggered
ventilation have included infants with MAS. One of these
found no advantage of synchronised intermittent mandatory
ventilation (SIMV) over IMV in 15 infants with MAS [40].
Another study found, in a group of 93 infants >2kgbirth
weight (including an unspeciﬁed number with MAS), that
use of SIMV was associated with a shorter duration of
ventilation compared with IMV [41]. Despite the relative
paucity of evidence in favour, it seems logical to use a
synchronized mode of ventilation in any spontaneously
breathing ventilated infant with MAS. Trigger sensitivity
should be set somewhat higher than that for a preterm
infant and should take into account the possibility of
autocycling if there is a tube leak [42] .T h e r eh a v eb e e n
no clinical trials in patients with MAS comparing SIMV
and synchronised intermittent positive pressure ventilation
(SIPPV), also known as assist control. Given the propensity
for gas trapping in MAS, there is some concern that using
SIPPV may lead to high levels of inadvertent positive end-
expiratory pressure (PEEP) with resultant hyperinﬂation.
For this reason SIMV may be the most appropriate mode of
ventilation in MAS.
3.4.2. Selection of Positive End-Expiratory Pressure. For any
newborn respiratory disease, but particularly MAS, appli-
cation of PEEP must balance the competing interests of
overcoming atelectasis whilst avoiding overdistension. Early
observations of the eﬀect of PEEP suggested the greatest
beneﬁt with PEEP settings between 4 and 7cm H2O,4 International Journal of Pediatrics
with higher PEEP settings (8–14cm H2O) giving minimal
oxygenation beneﬁt [43]. No more recent clinical studies
exist to guide PEEP selection in MAS. Physiological prin-
ciples dictate that if atelectasis predominates (Figure 1(b)),
increasing PEEP (up to a maximum of 10cm H2O) should
improve oxygenation, whereas for regional or global hyper-
inﬂation (Figure 1(c)) a lower PEEP (3-4cm H2O) may be
eﬀective (Table 1)[ 38]. For infants with severe atelectasis,
PEEP settings above 10cm H2O are likely to increase the
risk of pneumothorax [44], and modes of high frequency
ventilation are to be preferred if available.
3.4.3. Selection of Inspiratory Time. As with PEEP, setting
inspiratory time in MAS must take into account the balance
between atelectasis and overdistension. Term infants have
generally longer time constants than their preterm coun-
terparts [45] and thus require a longer inspiratory time
(around 0.5sec) to allow near-full equilibration of lung
volumechangeinresponsetotheappliedpeakpressure.Even
longer inspiratory times may be useful for lung recruitment
during inspiration if atelectasis is prominent.
3.4.4. Selection of Peak Inspiratory Pressure (or Tidal Volume).
Given the reduced compliance, the peak inspiratory pressure
(PIP) required to generate suﬃcient tidal volume in MAS is
often high (30cm H2Oo rm o r e ) .S u c hp r e s s u r e sm a yw e l l
contribute to a secondary ventilator-induced lung injury in
ventilated infants with MAS. Suggested target tidal volume
is 5-6mL/kg. If using a “volume guarantee” mode, the peak
pressurelimitshouldbesetatornear30cmH2Otoallowthe
ventilator to scale up the PIP when needed to reach the tidal
volume target. If PIP is persistently higher than 30cm H2O,
high frequency ventilation should be considered, if available.
3.4.5. Selection of Ventilator Rate. Especially if there is gas-
trapping and expiratory airﬂow limitation, optimal conven-
tional ventilation in MAS requires the use of a relatively low
ventilator rate (<50) and hence longer expiratory time. This
will help to avoid inadvertent PEEP. The resultant minute
ventilationmustbesuﬃcienttoproduceadequateCO2 clear-
ance. An acceptable arterial pCO2 range is 40–60mmHg
and pH 7.3-7.4, which is achievable in most infants even
when there is signiﬁcant parenchymal disease combined
with PPHN [46]. Hyperventilation-induced alkalosis, which
anecdotally appeared to reduce the need for extracorporeal
membraneoxygenation(ECMO)ininfantswithPPHN[47],
is no longer practiced, in part due to the risk of sensorineural
hearing loss [48].
3.5. High-Frequency Oscillatory Ventilation. Despite the
dearth of clinical trial, evidence suggesting a beneﬁt, high
frequency oscillatory ventilation (HFOV) has become an
important means of providing respiratory support for
infants with severe MAS failing conventional ventilation.
Published series from large neonatal databases suggest that
20–30% of all infants requiring intubation and ventilation
with MAS are treated with high-frequency ventilation [34,
36, 49], with most of these receiving HFOV rather than
high-frequency jet ventilation (HFJV). Indications for tran-
sitioning to HFOV include ongoing hypoxaemia and/or high
FiO2, and, less commonly, respiratory acidosis. In infants
with signiﬁcant atelectasis, adequate lung recruitment may
require the application of a mean airway pressure (PAW)
considerably higher than that on conventional ventilation
(up to 25cm H2Oi ns o m ec a s e s ) ,w i t has t e p w i s er e c r u i t -
ment manoeuvre likely to be the most eﬀective [50]. Once
oxygenation has improved, PAW should then be reduced;
most infants with MAS requiring HFOV can be stabilised
using a PAW around 16–20cm H2O, with gradual weaning in
the days thereafter [51]. Infants with prominent gas trapping
may tolerate the recruitment process poorly, with reductions
inoxygenationandsystemicbloodpressureandthepotential
for exacerbation of pulmonary hypertension. Recruitment
manoeuvres of some form can still be advantageous in this
group, with the beneﬁt becoming apparent when the PAW is
reduced.
Choice of oscillatory frequency is critically important
in MAS, with experimental studies and clinical experience
indicating that frequency should not be higher than 10Hz
and preferably should be set at 8 or even 6Hz. In experi-
mental models of MAS, high oscillatory frequency (15Hz)
is associated with worsening of gas trapping [52]. HFOV
can also lend a clinical advantage in infants with signiﬁcant
coexisting PPHN, as the response to inhaled nitric oxide
(iNO) is better when delivered on HFOV compared to
conventional ventilation [53]. Early reports suggested that
up to half of infants with MAS treated with HFOV did not
respond adequately and went on to receive ECMO [54, 55].
More recent experience would suggest that only around 5%
of infants treated with HFOV and iNO fail to respond and
undergo transition to ECMO [36].
3.6. High-Frequency Jet Ventilation. The combination of
atelectasis and gas trapping that can occur in MAS may be
better managed with HFJV than HFOV (Table 1), with the
former technique oﬀering the possibility of ventilation at a
lower PAW [56]. A number of laboratory investigations have
shown HFJV, either alone or in combination with surfactant
therapy, to be beneﬁcial in animal models of MAS [18, 56,
57]. Clinical studies including infants with MAS appear to
conﬁrm the beneﬁt of HFJV compared with conventional
ventilation, both in terms of improvement in oxygenation,
and avoidance of ECMO [58, 59]. Whilst there have been no
direct comparisons with HFOV in a clinical setting, we have
noted that some infants with intractable hypoxaemia and/or
respiratory acidosis do show improvements after transition
from HFOV to HFJV using a low-frequency (240–360bpm)
and a low conventional ventilator rate [60].
4. Adjunctive Respiratory Therapies
4.1. Bolus Surfactant Therapy. The pathophysiology of MAS
includes inhibition of surfactant in the airspaces, both by
meconium and exuded plasma proteins [4–6, 23]. Prelimi-
naryreportsoftheuseofexogenoussurfactantgivenasbolus
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although it was identiﬁed that around 40% of cases did not
respond [61]. Four randomised controlled trials of bolus
surfactant therapy have been conducted [62–65], which
when analysed together show a beneﬁt in terms of reduction
in need for ECMO but not duration of ventilation or other
pulmonary outcomes [66]. In the developed world, bolus
surfactant therapy is currently used in 30–50% of ventilated
infants with MAS [34, 36]. Bolus surfactant therapy should
be used judiciously in MAS, choosing infants with severe
disease, and treating early and, if necessary, repeatedly [12].
4.2. Lavage Therapy. Lung lavage using dilute surfactant is
an emerging treatment for MAS that oﬀers the potential of
interrupting the pathogenesis of the disease by removal of
meconium from the airspaces [12]. Laboratory studies and
preliminary clinical evaluations have indicated that lavage
therapy may improve oxygenation and shorten duration of
ventilation in MAS [67–69]. A recent randomised controlled
trial of large-volume lavage using dilute surfactant in infants
with severe MAS noted no eﬀect on duration of respiratory
support or other pulmonary outcomes but did ﬁnd a higher
rateofECMO-freesurvivalinthetreatedgroup[70].Further
clinical trials will be necessary to more precisely deﬁne the
eﬀect on survival.
4.3. Corticosteroid Therapy. Steroid therapy has been inves-
tigated in MAS for more than 3 decades, with a number
of small clinical trials being conducted, none of which have
given a deﬁnitive result. One recent trial suggested that
dexamethasone therapy could dampen the inﬂammatory
responseinMAS[71].Intheabsenceoffurthertrials,steroid
therapy cannot be recommended as routine therapy in MAS.
4.4. Inhaled Nitric Oxide. Large randomised controlled trials
have demonstrated the eﬀectiveness of iNO in term infants
with pulmonary hypertension, with a reduction in need
for ECMO and in the composite outcome of death or
requirement for ECMO [72]. Each trial included a large
subgroup with MAS; overall more than 640 infants with
MAS have been enrolled in iNO trials, although few have
reported the outcome for MAS separately. The potential
value of delivering iNO during HFOV has been highlighted
in one trial, in which the proportion of nonresponders
was lowest when the two therapies were combined [53].
Currently around 20–30% of all ventilated infants with MAS
receive iNO [34, 36], and around 40–60% show a sustained
response [46, 53].
The approach to an infant with MAS and coexistent
PPHN should initially focus on optimising the ventilatory
management and in particular overcoming atelectasis whilst
avoiding hyperinﬂation, both of which are associated with
an increase in pulmonary vascular resistance. The severity of
PPHNshouldbeassessedclinicallyandbyechocardiogramif
available.Ifmoderate-severePPHNpersistsafterappropriate
ventilatory manoeuvres and the pO2 remains at less than 80–
100mm Hg in FiO2 1.0 [53, 73], iNO should commence at a
dose of 10–20ppm. Higher doses do not appear to result in
better oxygenation [74].
4.5. Extracorporeal Membrane Oxygenation. Infants with
severe MAS have been treated with ECMO since 1976,
and MAS has been the leading diagnosis amongst neonates
referred for this therapy [75]. ECMO is now available
to infants with MAS in selected centres in 33 countries
worldwide [76], albeit at a high cost (at least 2.5 times
the daily cost of standard intensive care) [77]. With the
advent of newer therapies, the number of infants with MAS
treated with ECMO has decreased [78], but survival with
ECMO treatment for MAS has remained high (around
95%) [75]. The usual indication for commencing ECMO is
intractable hypoxaemia despite optimisation of the patient’s
condition with available therapies (including high-frequency
ventilation and iNO) and bolus surfactant therapy). Degree
of hypoxaemia in this setting has generally been quantiﬁed
using oxygenation index (OI), where OI = PAW × FiO2 ×
100/PaO2. An OI persistently above 40 despite aggressive
standard management has been, and remains, an indication
for treatment with ECMO where available [79]. Followup of
newborninfantstreatedwithECMObecauseofparenchymal
lung disease (excluding diaphragmatic hernia) suggests a low
rate of severe disability at one year (1.7% in the UK ECMO
trial) [80], with the risk of any disability being 17% [80].
4.6. Liquid Ventilation. To the author’s knowledge, there
is as yet no report of clinical use of perﬂuorocarbon in
MAS. Both total liquid ventilation with perﬂuorocarbon
and perﬂuorocarbon-assisted gas exchange have been inves-
tigated in animal models of MAS [81–83]. Both techniques
have shown short-term advantages over conventional ven-
tilatory management, with better oxygenation and lung
compliance [81, 83]. Total liquid ventilation appears to be
the most lung protective, resulting in much reduced me-
conium-associated histological damage compared with con-
ventional ventilation or PAGE [81]. The complications
of perﬂuorocarbon instillation noted in human subjects,
including pneumothorax, impaired carbon dioxide clear-
ance, and delayed excretion, may be signiﬁcant barriers to
the clinical use of liquid ventilation in ventilated infants with
MAS.
Perﬂuorocarbon has also been considered as a possi-
ble vehicle for lung lavage in MAS, especially given the
favourable biophysical properties including high oxygen
carrying capacity and low surface tension. Despite these
potential advantages, use of neither pure [84] nor emulsiﬁed
[69] perﬂuorocarbon as a lavage ﬂuid has shown any major
advantage over dilute surfactant. Even when followed by
perﬂuorocarbon-assisted gas exchange, the beneﬁts of per-
ﬂuorocarbon lavage appear minimal [83]. This may be due
to the relatively high density of perﬂuorocarbon and/or the
relative immiscibility of meconium with perﬂuorochemicals.
5.OutcomeofVentilationinMAS
5.1. Duration of Ventilation and Oxygen Therapy. Consid-
ering all intubated infants with MAS, median duration of
ventilation is 3 days (mean 4.8 days) [36]. Infants with
more severe disease, requiring at least one of high-frequency6 International Journal of Pediatrics
ventilation, iNO or bolus surfactant, are ventilated for a
median of 5 days [36]. Median duration of oxygen therapy
and length of hospital stay currently stand at 7 and 17 days,
respectively [36].
5.2. Mortality. Reﬁnements in intensive care and respira-
tory support have contributed to a signiﬁcant decrease in
mortality related to MAS, with population-based studies
now suggesting a mortality of 1-2 per 100,000 live births
[36, 85, 86]. The case-fatality rate in ventilated infants
with MAS varies widely in published series (0–37%) [37]
and is inﬂuenced by availability of alternative means of
ventilation, adjunctive therapies including nitric oxide, and
ECMO.Approximatelyone-quartertoone-thirdofalldeaths
in ventilated infants with a diagnosis of MAS are directly
attributable to the pulmonary disease, with the remainder
in large part caused by hypoxic-ischaemic encephalopathy
[34, 36, 86].
5.3. Short-Term Morbidities. Pneumothorax occurs in
around 10% of all ventilated infants with MAS [36, 87], and
the presence of this complication potentiates lung atelectasis
and PPHN and increases the risk of mortality [36, 88]. Other
air leak syndromes, including pneumomediastinum and
pulmonary interstitial emphysema, are seen occasionally.
Pulmonary haemorrhage (or, more correctly, haemorrhagic
pulmonary oedema) occurs in a small proportion of infants
with MAS and can occasionally cause severe destabilisation
and hypoxaemia [89].
5.4. Long-Term Morbidities. Respiratory compromise after
hospital discharge is common in infants who were ventilated
with MAS. Up to half of infants will be symptomatic
with wheezing and coughing in the ﬁrst year of life [90].
Older children may exhibit evidence of airway obstruction,
hyperinﬂation, and airway hyperreactivity, but appear to
have normal aerobic capacity [91]. Neurological sequelae
following MAS are well recognized [37], and a diagnosis of
MAS in the neonatal period confers a considerable risk of
cerebral palsy (5–10%) [92, 93] and global developmental
delay (15%) [92].
6. Conclusion
With judicious use of available modes of ventilation and
adjunctive therapies, infants with even the most severe MAS
can usually be supported through the disease, with an ac-
ceptable burden of short-and long-term morbidity.
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